^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Papillary Thyroid Cancer: Consider systemic therapy…For progressive and/or symptomatic disease, consider lenvatinib (preferred) or sorafenib